Tech Company Financing Transactions
Initial Therapeutics Funding Round
Initial Therapeutics secured a $75 million Series A venture capital round on 5/1/2023. Investors included Apple Tree Partners.
Transaction Overview
Company Name
Announced On
5/1/2023
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Apple Tree Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate growth, both organically and externally, and expand operations.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
285 east grand avenue south
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Initial Therapeutics is discovering and developing a new class of small-molecule medicines designed to halt pathogenic protein formation in the earliest stages. Initial's approach is unique and starkly differentiated from protein degradation and other interventions that recognize and tackle proteins only after they have been fully formed.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Spiros Liras
Co-Founder
Brian Paegel
Co-Founder
Kevan Shokat
Browse more venture capital transactions:
Prev: 4/30/2023: Careerist venture capital transaction
Next: 5/1/2023: Fanton venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs